Earnings ·
Dr. Reddy's Laboratories reported Q1FY27 consolidated revenues of ₹80,705 million, a 6% year-over-year decline driven…
RDYDR Reddys Laboratories Ltd
Dr. Reddy's Laboratories reported Q1FY27 consolidated revenues of ₹80,705 million, a 6% year-over-year decline driven by lower lenalidomide sales. Profit after tax attributable to equity holders fell 69% YoY to ₹4,435 million. Results were negatively impacted by a ₹2,397 million provision for inventory and costs related to semaglutide active pharmaceutical ingredient (API) issues, which reduced gross profit, EBITDA, and PBT margins by approximately 3%. The company appointed Dr. Sridevi Khambhampaty as Global Head of Biologics and M/s Deloitte Haskins & Sells, LLP as its Independent Registered Public Accounting Firm on July 22, 2026. The company also reported receiving a USFDA Form 483 with seven observations at its Bachupally biologics facility. This company is a global pharmaceutical company that develops and sells APIs, generics, biosimilars, and OTC products.